REPORT FROM ELEKTA'S ANNUAL MEETING 2009

REPORT FROM ELEKTA'S ANNUAL MEETING 2009

PRESS RELEASE			
Stockholm, Sweden, September 15, 2009

At the Annual General Meeting of Elekta AB (publ), 60 shareholders entitled to
vote participated, representing 52 percent of the votes in the company. 
• Dividend to shareholders of SEK 2.00 (1.75) per share. 
• Akbar Seddigh, Carl G. Palmstierna, Tommy H. Karlsson, Laurent Leksell, Hans
Barella, Birgitta Stymne Göransson, Luciano Cattani and Vera Kallmeyer were
reelected to the Board. 

Elekta's President and CEO Tomas Puusepp opened his speech by describing the
development of Elekta from a company specialized in neurosurgery to a partner
and comprehensive provider of clinical solutions for treatment of cancer and
brain disorders.

“Our mission is to improve the quality of life and in more and more cases
contribute to a life free from cancer and brain disorders. An important role for
Elekta is also to make cancer care available. By expanding geographically and by
contributing to the improvement of efficiency for health care providers, more
patients will have access to treatment.”

Every day more than 100,000 patients receive treatment for cancer and brain
disorders with a solution from Elekta.

“This is an important driver for me and my co-workers. We strive to become
better and better at developing solutions that contributes to cancer care. We
work to continuously make health care more efficient so that hospitals can treat
more patients in shorter time and thereby making it possible to meet the
increasing need for treatment.”

Software is growing in importance as a tool for efficiency as well as accuracy,
and for bringing research and development forward.

“Today Elekta is the leading provider of software for oncology. Software will
continue to play an important role in the future when treatment even better can
be adapted for every individual and every specific cancer.”

Elekta is becoming more involved in the complete treatment process and in the
customers' value chain.

“This is an important element of Elekta's sustainable profitable growth. We are
growing and we will continue to grow with our more than 5,000 customers.”

Elekta's geographical expansion continues, and Tomas Puusepp highlighted the
recent activities of the company.

“Investments in Brazil has proven to be a great success with strong order
bookings. This year we have initiated a strategic cooperation with Swedfund
International, offering financing and competency for establishment of cancer
care in Africa, Asia, Latin America and in parts of Eastern Europe. Together we
work to establish cancer care in countries where there is little access to
cancer care today.”

Tomas Puusepp commented on the performance in the fiscal year 2008/09 and the
first quarter 2010. 

“Despite of the worldwide economic crisis Elekta has had a solid performance in
all product areas and in all regions. We are showing good results with
improvements in order bookings, net sales, operating profit and net income.”

He also commented on the ongoing efficiency program.

“We have taken a number of steps to improve the efficiency, by further
streamlining of the organization and by developing synergies based on our
acquisitions. By creating larger units and regionalizing the Asian business we
improve our possibilities to capture new opportunities in the market. We will
reduce cost on an annual basis by SEK 100 M with full effect next fiscal year.
The restructuring cost is expected to be SEK 40 M.”

The financial outlook for this year remains unchanged. For 2009/10 it means an
expected growth in net sales of more than 8 percent in local currency. Operating
profit in kronor is expected to improve with more than 35 percent. The long term
financial outlook also remains unchanged.

“Elekta's aim is to achieve sustainable profitable growth. We conduct the
operations with a long term plan, regularly reviewed and evaluated by the Board
of Directors and with a perspective of at least three years. The financial
objectives form the base in the long term planning. Organic sales growth shall
on average exceed 10 percent in local currency, operating result improvement
rate shall exceed sales growth in SEK, return on capital employed shall exceed
20 percent and net debt/equity ratio shall not exceed 0.50.”

Tomas Puusepp concluded by thanking shareholders for their confidence, and
people in Elekta for good performance in the year.

“Elekta is now stronger than ever. And I am convinced that Elekta in the future
will play an even greater role in cancer care and treatment of brain disorders,
making the care available to more people around the world.”


Disposition of the company's earnings

Elekta's dividend policy is to distribute 20 percent or more of net profit in
the form of dividends, share buy-backs or comparable measures.

The Meeting resolved in accordance with the Board's proposal, that from the
company's disposable earnings of SEK 864,476,243 a dividend be paid to the
shareholders in an amount corresponding to SEK 2.00 per share and that the
balance be carried forward. The record date for the dividend was set at
September 18, 2009.


Election of the Board

Following the proposal from the Nomination Committee, the Annual General Meeting
reelected Akbar Seddigh, Carl G. Palmstierna, Tommy H Karlsson, Laurent Leksell,
Hans Barella, Birgitta Stymne Göransson, Luciano Cattani and Vera Kallmeyer.
Akbar Seddigh was reelected as Chairman of the Board.

The Meeting decided that the total remuneration to the Board shall be SEK
2,685,000 of which 570,000 to the Chairman, SEK 285,000 each to the external
Board members, SEK 70,000 to the Chairman of the Executive Compensation
Committee and SEK 35,000 to other members of the Executive Compensation
Committee, SEK 120,000 to the Chairman and SEK 60,000 to other members of the
Audit Committee. No remuneration is paid to Board members employed by the
company.

Remuneration to auditors

Remuneration to the auditor was resolved to be paid according to an approved
account.  

Principles for executive compensation

Board Chairman Akbar Seddigh reported on Elekta's strategy for compensation to
managers, in which the aim is to strengthen management by objectives, profit
development in the short and long term as well as create long-term value growth
and align management with the shareholder perspective. The Chairman also
reported on the work of Elekta's Executive Compensation Committee.

The Meeting approved the principles for remuneration as proposed by the Board
and presented on the company's website. The principles will be valid for
employment agreements entered into after the Meeting and for any changes made to
existing employment agreements thereafter.

Authorization of the Board to purchase and transfer own shares

The Meeting authorized the Board of Directors during the period until the next
Annual General Meeting, on one or more occasions, to decide on acquisition of a
maximum number of own shares to the extent that after purchase, the company
holds not more than 10 percent of the total number of shares in the company. The
Meeting also authorized transfer of own shares during the period until the next
Annual General Meeting.

Incentive program

The Meeting decided in accordance with the proposal on the issue of performance
based share program. Performance Share Program 2009 is proposed to cover
approximately 75 key employees in the Elekta group with an opportunity to be
allotted, free of charge, class B shares in Elekta. Assuming maximum allotment
of shares under Performance Share Program 2009 and a share price of SEK 105, the
cost, including social security cost and financing cost for repurchased own
shares is estimated at approximately SEK 24,400,000. The program is described in
detail on Elekta's website www.elekta.com.

Composition of Election Committee

The Meeting decided that an Election Committee should be appointed through a
procedure whereby the chairman of the Board, before the end of the second
quarter of the financial year, contacts three to five representatives for the,
at that time, largest holders of A and B shares. Those representatives shall
together with the Chairman of the Board constitute the Election Committee and
fulfill its obligations in accordance with the Swedish Code of Corporate
Governance. The names of the members of the Election Committee shall be
published as soon as they have been appointed, however, not later than six
months before the next Annual General Meeting. The Election Committee is
appointed until a new Election Committee has been appointed. No remuneration
shall be paid for the performance of the work in the Election Committee.

For further information, please contact:

Stina Thorman, Investor Relations, Elekta AB
Tel: +46 8 587 254 37, +46 70 778 60 10, e-mail: stina.thorman@elekta.com

About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.